Double blind randomised controlled trial of Levosimendan versus Dopexamine in septic shock

Dr GED DEMPSEY, University Hospital Aintree0 个研究点目标入组 20 人开始时间: 2005年2月15日最近更新: 2019年11月25日

适应症

试验速览

暂无简介。

•1). Presence of septic shock (as given by)
•Septic shock is characterised by:
•·Hypotension:
•Mean arterial pressure <60mmHg or the requirement for inotropic or vasopressor drugs to maintain a pressure above this, despite adequate volume resuscitation.
•·Perfusion abnormalities:
•Lactic acidosis, oliguria and mental impairment associated with sepsis.
•·Systemic Inflammatory Response Syndrome (SIRS) as a result of a known or presumed bacteraemia.
•SIRS is defined as two or more of following:
•i).Hypothermia (<36C) or hyperthermia (>38C).
•ii).Heart rate >90 bpm.
•iii).Respiratory rate >20 bpm
•iv).Leucopenia (<4000/mm3) or leucocytosis (>12,000/mm3).
•2). When the use of Dopexamine added to the inotropic regimen may be considered to be beneficial. This will be due to the presence of one or more of the following.
•i).Renal dysfunction / oliguria. (Urine output of <0.5 ml/Kg/hr for 2 consecutive hours, in adequately resuscitated patients).
•ii).Lactic acidosis.(pH<7.35 with lactate>2mmol/l).
•iii).Increasing intramucosal gastric acidosis. ( Decreased pHi ).
•Such that an agent considered to preserve splanchnic perfusion may be deemed necessary.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

发起方

Dr GED DEMPSEY, University Hospital Aintree